GW Pharmaceuticals PLC (GWPH)
| Market Cap | 6.53B |
| Revenue (ttm) | 527.21M |
| Net Income (ttm) | -58.13M |
| Shares Out | 31.53M |
| EPS (ttm) | -1.86 |
| PE Ratio | n/a |
| Forward PE | 833.33 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 20 |
| Last Price | $218.40 |
| Previous Close | $218.53 |
| Change ($) | -0.13 |
| Change (%) | -0.06% |
| Day's Open | 218.55 |
| Day's Range | 218.27 - 218.78 |
| Day's Volume | 463,005 |
| 52-Week Range | 87.07 - 219.00 |
Marijuana stocks may still have some roadblocks until the U.S. market opens, but change is coming, and medical marijuana is leading the way. The post 7 Medical Marijuana Stocks For Your Waiting Room app...
GW Pharmaceuticals PLC (NASDAQ:GWPH), the medicinal cannabis giant, has received European Commission (EC) approval for the treatment of seizures associated with tuberous sclerosis complex. The EC has ap...
– Tuberous sclerosis complex (TSC) represents a third indication for GW's cannabidiol in Europe –
– Tuberous sclerosis complex (TSC) represents a third indication for GW's cannabidiol in Europe –
EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies
2020 was a big year for the cannabis industry, but 2021 is shaping up to be even bigger.
Although research on the medical benefits of the drug is limited in the U.S., we have some ideas about marijuana's ability to disrupt the healthcare industry.
Cannabinoid-based medicines have made major advancements in research and uptake over the past few years.
The stock of GW Pharmaceuticals PLC (NAS:GWPH, 30-year Financials) gives every indication of being possible value trap, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate o...
These are the top players in the expanding $19.6 billion U.S. marijuana market.
The cannabis-based pharmaceutical company agreed to be acquired.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for GW Pharmaceuticals Plc's (NASDAQ: GWPH) Epidyolex (cannabidiol). It is an a...
– If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – – If approved by the European Commission (EC), the label for EPIDYOLEX® will...
– If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – – If approved by the European Commission (EC), the label for EPIDYOLEX® will...
This month, two groundbreaking deals in cannabis were announced — the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals and the combination of the multi-state operator (MSO) Parallel with the sp...
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will cont...
Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) recently-announced deal to acquire cannabis-derived drug maker GW Pharmaceuticals plc (NASDAQ:GWPH) for US$7.2 billion in cash and stock has boosted investor int...
The company's net loss was far narrower than many expected.
Interest in cannabis stocks has sparked into life this month as London welcomed its first two specialist medical marijuana companies. A surge in share prices was seen around the world last week, as the ...
Shares of GW Pharmaceuticals (NASDAQ:GWPH) fell 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 14.29% year over year to ($0.08), which b...
– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year –
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Act...
Few investors saw this one coming.
A blockbuster deal announced earlier this week could be a sign of a bright future for cannabidiol-oriented pharmaceutical companies. On Wednesday, cancer therapy developer Jazz Pharmaceuticals PLC (NASD...
Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) recently-announced deal to acquire cannabis-derived drug maker GW Pharmaceuticals plc (NASDAQ:GWPH) for US$7.2 billion in cash and stock has boosted investor int...
Jazz is paying $7.2 million to buy the maker of CBD-derived drug Epidiolex. Is it a smart deal?
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will deve...
Marijuana stocks are soaring higher on a string of Democratic electoral wins. But not every company in this troubled sector is a winner.
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GW Pharmaceuticals plc (NASDAQ: GWPH) concerning potent...
WILMINGTON, Del., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ GM: GWPH) regarding possible breaches of ...
Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals, maker of the first epilepsy drug derived from marijuana, for $7.2 billion in cash and stock.
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GW Pharmaceuticals plc ("GWPH" or the "C...
The deal to buy GW Pharmaceuticals creates a leader in neuroscience.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether GW Pharmaceuticals plc (NASDAQ: GWPH) and its board of directors violated the federal securities ...
NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of GW Pharmaceu...
GW Pharmaceuticals (GWPH) stock is soaring higher on Wednesday following news that Jazz Pharmaceuticals (JAZZ) is acquiring the company. The post GWPH Stock: 12 Things to Know About the GW Pharma-Jazz P...
Marijuana stocks rallied as Jazz Pharmaceuticals said it would buy GW Pharma. GWPH stock jumped.
Jazz Pharmaceuticals Plc said on Wednesday it would buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal to bolster its neuroscience business by adding a cannabis-based epilepsy treatment.
Investors cheered an unexpected acquisition of the cannabinoid-focused biotech.
Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 billion
Jazz Pharmaceuticals said on Wednesday it would buy GW Pharmaceuticals in a $7.2 billion cash-and-stock deal to bolster its neuroscience business by adding cannabis-based epilepsy treatment. CNBC's Jim ...
Dublin-based Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) announced Wednesday morning that it has agreed to acquire London-based GW Pharmaceuticals PLC (NASDAQ: GWPH) for $220 per American depositary share (...
About GWPH
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of s... [Read more...]
| Industry Drug Manufacturers-General | IPO Date May 1, 2013 |
| CEO Justin Gover | Employees 1,161 |
| Stock Exchange NASDAQ | Ticker Symbol GWPH |
Financial Performance
In 2020, GWPH's revenue was $527.21 million, an increase of 69.34% compared to the previous year's $311.33 million. Losses were -$58.13 million, 544.5% more than in 2019.
Analyst Forecasts
According to 17 analysts, the average rating for GWPH stock is "Buy." The 12-month stock price forecast is 204.90, which is a decrease of -6.18% from the latest price.